Lifirafenib
Catalog No. A20988
Lifirafenib (BGB-283) is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively.
| Catalog Num | A20988 |
|---|---|
| M. Wt | 478.42 |
| Formula | C25H17F3N4O3 |
| Purity | >98% |
| Storage | at -20°C 3 years Powder |
| CAS No. | 1446090-77-2 |
| Synonyms | BGB-283, BGB283, BGB 283 |
| SMILES | FC(F)(F)C(C=C1)=CC2=C1N=C(N2)[C@@H]3[C@H]([C@@H]43)OC(C4=C5)=CC=C5OC6=CC=NC(N7)=C6CCC7=O |
Lifirafenib (BGB-283) is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 20.9 mL | 104.51 mL | 209.02 mL |
| 0.5 mM | 4.18 mL | 20.9 mL | 41.8 mL |
| 1 mM | 2.09 mL | 10.45 mL | 20.9 mL |
| 5 mM | 0.42 mL | 2.09 mL | 4.18 mL |
*The above data is based on the productmolecular weight 478.42. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Contact information
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: sales@adooq.com
ADOOQ 产品质量保证
We promise all products to perform as described.